Letter to the Editor
Characterizing drug-induced capillary leak syndromes using the World Health Organization VigiBase

https://doi.org/10.1016/j.jaci.2018.09.001Get rights and content

First page preview

First page preview
Click to open first page preview

Cited by (26)

  • Immune-related generalised oedema – A new category of adverse events with immune checkpoint inhibitors

    2023, European Journal of Cancer
    Citation Excerpt :

    Several reports describe recurrent pericardial or pleural drug-related effusions induced by ICPI, particularly in patients treated for thoracic cancer [8–16]. Some cases of immune-mediated polyserositis with severe generalised oedema related to ICPI have been occasionally previously reported [5,7,17,18], with the largest series comprising four cases, and some cases resembling with endothelial syndrome, such as SOS/VOD disease [5] or capillary leak syndrome (CLS) [17,19]. However, the clinical characteristics, frequency, severity, and outcome of patients with these immune-related generalised oedemas remain poorly known.

  • Immune checkpoint inhibitors-induced systemic capillary leak syndrome: A report of two cases

    2023, Revue de Medecine Interne
    Citation Excerpt :

    Typically, patients develop transient edema and shock associated with a pathognomonic combination of hemoconcentration and hypoalbuminemia. SCLS can be either idiopathic (Clarkson's disease) or secondary to various causes including medications [1]. Herein, we report two cases of ICIs-associated SCLS and discuss key issues regarding its clinical presentation, pathophysiology, and treatment.

  • Anticancer Drug-Induced Capillary Leak Syndrome

    2022, Kidney International Reports
    Citation Excerpt :

    CLS is a rare18,19 but potentially lethal side effect of gemcitabine. It is the drug most often reported to be associated with CLS in the study by Mertz et al.14 The exact pathophysiology of gemcitabine-induced CLS is unclear.

  • Uses of pharmacovigilance databases: An overview

    2020, Therapies
    Citation Excerpt :

    This study was able to describe relevant demographic and clinical data (sex predominence, median age at onset of DIL, time to onset) and profile changes over years of suspected drug-induced SLE reports with evolution of pharmacopeia [26]. A study with a similar design revealed a list of 52 suspected liable drugs at risk of inducing capillary syndrome [27]. These data might prove useful for clinicians when confronted to cases of suspected DIL and capillary leak syndrome.

View all citing articles on Scopus

This study is part of the Monitoring the IMmUological TOXicity of Drugs (MIMUTOX) research program registered under NCT03480529.

Disclosure of potential conflict of interest: The authors declare that they have no relevant conflicts of interest.

View full text